BioXcel Therapeutics, Inc. (BTAI) › Shareholders' EquityBioXcel Therapeutics, Inc. (BTAI) — Shareholders' EquityAnnual figures by period end, from SEC filings.2017-03-29: -$314.0K2017-12-31: -$982.0K2018-12-31: $38.89M2019-12-31: $26.89M2020-12-31: $206.70M2021-12-31: $221.67M2022-12-31: $76.78M2023-12-31: -$56.51M2024-12-31: -$93.10M2025-12-31: -$95.46M-$95.46M2017-03-29Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31-$95.46M—2026-03-27Balance as of period end2024-12-31-$93.10M—2026-03-27Balance as of period end2023-12-31-$56.51M-173.6%2026-03-27Balance as of period end2022-12-31$76.78M-65.4%2025-03-28Balance as of period end2021-12-31$221.67M+7.2%2024-03-22Balance as of period end2020-12-31$206.70M+668.5%2023-03-16Balance as of period end2019-12-31$26.89M-30.8%2022-03-11Balance as of period end2018-12-31$38.89M—2021-03-12Balance as of period end2017-12-31-$982.0K—2020-03-09Balance as of period end2017-03-29-$314.0K—2019-03-12Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)